CSIMarket
 


Epizyme Inc.  (EPZM)
Other Ticker:  
 
 

EPZM's Capital Expenditures Growth by Quarter and Year

Epizyme's Capital Expenditures results by quarter and year




EPZM Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 0.10 0.29 0.17
III Quarter September - 0.17 0.27 0.23
II Quarter June 0.00 0.10 75.27 0.17
I Quarter March 0.01 0.12 -24.94 0.02
FY   0.01 0.49 50.89 0.59



EPZM Capital Expenditures second quarter 2022 Y/Y Growth Comment
Epizyme Inc. in the second quarter 2022 recorded Capital Expenditures of $ 0.00 millions.

Looking into second quarter 2022 results within Major Pharmaceutical Preparations industry 193 other companies have achieved higher Capital Expenditures growth. While Epizyme Inc.' s Capital Expenditures no change of % ranks overall at the positon no. 3004 in the second quarter 2022.




EPZM Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -65.52 % 70.59 % 13.33 %
III Quarter September - -37.04 % 17.39 % 475 %
II Quarter June - -99.87 % 44176.47 % -
I Quarter March -91.67 % - - -81.82 %
FY   - -99.04 % 8525.42 % 96.67 %

Financial Statements
Epizyme's second quarter 2022 Capital Expenditures $ 0.00 millions EPZM's Income Statement
Epizyme's second quarter 2021 Capital Expenditures $ 0.10 millions Quarterly EPZM's Income Statement
New: More EPZM's historic Capital Expenditures Growth >>


EPZM Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -41.18 % 7.41 % -26.09 %
III Quarter September - 70 % -99.64 % 35.29 %
II Quarter June - -16.67 % - 750 %
I Quarter March -90 % -58.62 % - -86.67 %
FY (Year on Year)   - -99.04 % 8525.42 % 96.67 %




Capital Expenditures second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #194
Healthcare Sector #506
Overall #3004

Capital Expenditures Y/Y Growth Statistics
High Average Low
13250.79 % 1481.47 % -99.5 %
(Jun 30 2020)   (Mar 31 2022)
Capital Expenditures second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #194
Healthcare Sector #506
Overall #3004
Capital Expenditures Y/Y Growth Statistics
High Average Low
13250.79 % 1481.47 % -99.5 %
(Jun 30 2020)   (Mar 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Epizyme's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


EPZM's II. Quarter Q/Q Capital Expenditures Comment
II. Quarter 2022 accomplishment of 0.00 millions by Epizyme Inc. come out even worse considering the 0.01 millions in the first quarter.

Within Major Pharmaceutical Preparations industry Epizyme Inc. achieved highest sequential Capital Expenditures growth. While Epizyme's Capital Expenditures growth quarter on quarter, overall rank is .


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


EPZM's II. Quarter Q/Q Capital Expenditures Comment
Current accomplishment of 0.00 millions by Epizyme Inc. appear even more unfavourable if you take a look at 0.01 millions Capital Expenditures in the first quarter.

Within Major Pharmaceutical Preparations industry Epizyme Inc. achieved highest sequential Capital Expenditures growth. While Epizyme's Capital Expenditures growth quarter on quarter, overall rank is .


Epizyme's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.38 $ 0.49 $ 0.67 $ 0.77
Y / Y Capital Expenditures Growth (TTM) - -99.5 % -99.04 % -98.67 % -98.48 %
Year on Year Capital Expenditures Growth Overall Ranking # 3004 # 2535 # 2081 # 2558 # 8
Seqeuential Capital Expenditures Change (TTM) - -22.43 % -27.79 % -12.82 % -98.98 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 3004 # 3053 # 1985 # 2166 # 2071




Cumulative Capital Expenditures growth Comment
Epizyme Inc. realized trailing twelve months Capital Expenditures of $ 0 millions, in the Jun 30 2022, compare to Capital Expenditures of $ 1 millions a year ago.

In the Healthcare sector 505 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 2535 to 3004.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
13250.79 %
1481.47 %
-99.5 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 194
Healthcare Sector # 506
Overall # 3004

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
13250.79 %
1481.47 %
-99.5 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 194
Sector # 506
S&P 500 # 3004
Cumulative Capital Expenditures growth Comment
Epizyme Inc. realized trailing twelve months Capital Expenditures of $ 0 millions, in the Jun 30 2022, compare to Capital Expenditures of $ 1 millions a year ago.

In the Healthcare sector 505 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 2535 to 3004.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
13250.79 %
1481.47 %
-99.5 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 194
Healthcare Sector # 506
Overall # 3004

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
13250.79 %
1481.47 %
-99.5 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 194
Sector # 506
S&P 500 # 3004




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
EPZM's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for EPZM's Competitors
Capital Expenditures Growth for Epizyme's Suppliers
Capital Expenditures Growth for EPZM's Customers

You may also want to know
EPZM's Annual Growth Rates EPZM's Profitability Ratios EPZM's Asset Turnover Ratio EPZM's Dividend Growth
EPZM's Roe EPZM's Valuation Ratios EPZM's Financial Strength Ratios EPZM's Dividend Payout Ratio
EPZM's Roa EPZM's Inventory Turnover Ratio EPZM's Growth Rates EPZM's Dividend Comparisons



Companies with similar Capital Expenditures no change for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Jun 30 2022
Novan Inc -0.21%$ -0.213 millions
Endo International Plc-0.32%$ -0.317 millions
Molecular Templates inc -0.59%$ -0.590 millions
Atricure Inc -0.69%$ -0.688 millions
Seagen Inc -0.83%$ -0.833 millions
Boston Scientific Corporation-0.94%$ -0.943 millions
Ispecimen inc -1.10%$ -1.098 millions
3m Company-2.54%$ -2.538 millions
Eli Lilly And Company-2.70%$ -2.701 millions
Dynatronics Corporation-2.88%$ -2.878 millions
Amicus Therapeutics inc -3.01%$ -3.005 millions
Hanger inc.-3.02%$ -3.016 millions
Encompass Health Corporation-3.39%$ -3.390 millions
Surmodics Inc-4.44%$ -4.440 millions
Davita Inc -4.80%$ -4.797 millions
Tenaya Therapeutics Inc -5.07%$ -5.067 millions
Abiomed Inc -5.40%$ -5.397 millions
Healthcare Services Group Inc -5.63%$ -5.632 millions
Cidara Therapeutics Inc -5.88%$ -5.882 millions
Viatris Inc -6.05%$ -6.047 millions
Mimedx Group Inc -6.17%$ -6.173 millions
Vericel Corporation-6.47%$ -6.468 millions
Caremax Inc -6.61%$ -6.614 millions
Sight Sciences Inc -7.32%$ -7.317 millions
Abbott Laboratories-8.23%$ -8.232 millions
National Healthcare Corp-8.45%$ -8.451 millions
1life Healthcare Inc -8.56%$ -8.561 millions
Urogen Pharma Ltd -8.70%$ -8.696 millions
F star Therapeutics Inc -8.95%$ -8.951 millions
Becton Dickinson And Company-8.99%$ -8.989 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com